-
Final Tests Planned into Potential OCMD Gene Therapy, Could Support Trial in Patients
Benitec Biopharma’s plans 3 tests in a oculopharyngeal muscular dystrophy dog model, final steps to bringing its gene therapy, BB-301, into a Phase 1 trial. Read more here.
What do you think about this research project?
Sorry, there were no replies found.
Log in to reply.